Cellular Dynamics Raises $30 Million to Expand Its Product Line of Human Stem Cells and Tissue Cells Cellular Dynamics International, Inc., the world’s only industrial manufacturer of human induced pluripotent stem cells and tissue cells, has closed on a $30 million private equity round. [Cellular Dynamics International, Inc. Press Release] Fred Hutchinson Cancer Research Center to Lead Immunotherapy Clinical Trials Network Research institutions at 27 sites in the U.S. and Canada have been selected to participate in the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute and headquartered at Fred Hutchinson Cancer Research Center. [Fred Hutchinson Cancer Research Center Press Release] MRC-CRM and iCeMS Sign Agreement on Academic Collaboration The University of Edinburgh’s Medical Research Council Centre for Regenerative Medicine (MRC-CRM) and Kyoto University Institute for Integrated Cell-Material Sciences (iCeMS) signed a memorandum of understanding covering future collaborative research. [MRC Centre for Regenerative Medicine Press Release] SuperGen and Astex Therapeutics Enter Definitive Merger Agreement SuperGen, Inc. and Astex Therapeutics Limited jointly announced that they have entered into a definitive agreement to merge the two companies, subject to customary closing conditions, including regulatory and shareholder approvals. [SuperGen, Inc. Press Release] Sanofi-Aventis Completes Acquisition of Genzyme Corporation Sanofi-aventis announced that it has completed its acquisition of Genzyme Corporation, which is now a wholly-owned subsidiary of sanofi-aventis. [Sanofi-aventis Press Release] Mesoblast Update on Valeant Proposal to Cephalon Mesoblast wishes to inform the market that the Board of its strategic partner Cephalon Inc. has rejected the unsolicited proposal from Valeant Pharmaceuticals International Inc. to acquire its issued share capital or certain assets. [Mesoblast Limited Press Release] American Cancer Society Awards New Research and Training Grants The American Cancer Society has awarded 132 national research and training grants totaling $51,473,000 to 85 institutions nationwide in the second of two grants cycles for 2011. [American Cancer Society Press Release] UCSD Scientists Receive Prestigious Hartwell Biomedical Research Awards Three scientists at the University of California, San Diego (UCSD) School of Medicine are among this year’s 12 winners of Hartwell Individual Biomedical Research Awards, honoring researchers whose work advances children’s health. [University of California, San Diego Press Release] Drug Developer Aldagen Withdraws IPO For Second Time Aldagen Inc. has withdrawn its proposed initial public offering after 18 months in registration, a period in which the drug developer suffered a series of setbacks in the clinic and shuffled its senior management multiple times. [The Wall Street Journal] Blueprint Medicines Secures $40 Million Series A Financing to Translate New Molecular Data into Personalized Cancer Treatments Blueprint Medicines, a company harnessing the understanding of the molecular blueprint of cancer to develop personalized, highly-selective cancer therapies, announced the closing of a $40 million Series A financing led by Third Rock Ventures. [BusinessWire] Cardio3 BioSciences Announces International C-Cure® Phase II Clinical Trial at the 60th Annual American College of Cardiology Meeting The Belgian biotechnology company, Cardio3 BioSciences presented detailed data from the Phase II clinical trial of C3BS-CQR-1 (C-Cure®), its novel stem cell therapy for ischemic cardiomyopathy, at the 60th annual American College of Cardiology in New Orleans, USA. [Cardio3 BioSciences Press Release] CEL-SCI Corporation Receives Government Approval in India to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer CEL-SCI Corporation announced that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® in India from the Directorate General of Health Services Office of Drug Controller General (India). [CEL-SCI Corporation Press Release] Proteonomix, Inc. Files New Patent Application for a New Technology to Focus on Mobilization of Bone Marrow Stem Cells and Begins to Prepare for a Clinical Trial Based on the Patent Application Proteonomix, Inc. announced that it has filed a provisional patent application in anticipation of commencement of its initial clinical trial of a drug combination thought to extend life expectancy for a class of terminally ill patients awaiting liver transplants. [BusinessWire] Parkinson’s Patients Needed for Trial of Possible Gene Therapy Researchers at the Stanford University School of Medicine are recruiting people who have Parkinson’s disease to participate in a clinical trial of a potential gene therapy. [Stanford University School of Medicine Press Release] HemaCare Names Dr. Scott Burger Scientific Advisory Board Chair HemaCare Corporation named Scott R. Burger, MD as the Chairperson of its Scientific Advisory Board. HemaCare has also engaged Dr. Burger, a world renowned cell therapy expert, in a comprehensive consulting services agreement. [BusinessWire] Walk Away With A RoboSep™ Facebook Photo Contest Winners STEMCELL Technologies has announced the Grand Prize Winner and Finalists of the “Walk Away With A RoboSep™” Facebook photo contest. [STEMCELL Technologies, Inc. Press Release] First Patient to Get Stem Cell Therapy Comes Forward In the six months since scientists announced they had infused a drug made from human embryonic stem cells into a partially paralyzed patient’s spine, the identity of the recipient has been shrouded in secrecy. Now, a 21-year-old Alabama nursing student who was paralyzed from the chest down in a car crash in September has come forward to identify himself as the volunteer. [The Washington Post] Announcing the First Stem Cell Translational Journal AlphaMed Press announces the launch of a major peer-reviewed journal, STEM CELLS Translational Medicine, answering an acknowledged need within the research and clinical communities for comprehensive coverage of stem cell science, stem cell-based regenerative medicine and tissue engineering, stem cell-based predictive toxicology, and cancer stem cell investigation. [AlphaMed Press Press Release] |